First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC

First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC

A panelist discusses how waiting for molecular testing results before initiating treatment for non–small cell lung cancer (NSCLC) is crucial because patients with EGFR mutations can avoid chemotherapy and immunotherapy in favor of targeted oral agents like osimertinib, which offer survival benefits with minimal toxicity compared to traditional treatments, while premature immunotherapy could cause severe immune-related adverse events that might p…